Takara Bio Inc 2025 IR
The report outlines Takara Bio's business strategies and sustainability initiatives for fiscal 2025. The company focused on expanding its Reagents/Instruments and CDMO businesses, including the acquisition of Curio Bioscience to enter the spatial analysis field and ViSpot to enhance viral safety testing. Takara Bio advanced its 'glocal' manufacturing system to mitigate geopolitical risks and diversify supply chains across Japan, the U.S., China, Europe, and India. In sustainability, the company worked toward reducing CO2 emissions intensity, promoting human rights due diligence, and fostering a diverse workforce, achieving a 23.8% ratio of women in managerial positions.
Company: Takara Bio Inc
Sector: Health Care
Country: Japan
Year: 2025
Type: IR
Pages: 25
Takara Bio Inc
Corporate Report
The report outlines Takara Bio's business strategies and sustainability initiatives for fiscal 2025. The company focused on expanding its Reagents/Instruments and CDMO businesses, including the acquisition of Curio Bioscience to enter the spatial analysis field and ViSpot to enhance viral safety testing. Takara Bio advanced its 'glocal' manufacturing system to mitigate geopolitical risks and diversify supply chains across Japan, the U.S., China, Europe, and India. In sustainability, the company worked toward reducing CO2 emissions intensity, promoting human rights due diligence, and fostering a diverse workforce, achieving a 23.8% ratio of women in managerial positions.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Apr 1, 2024 - Mar 31, 2025
Fiscal Year
2025
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Water Consumption
Total Waste
Women in Management
Employees